Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis

Gut

Volumn 52, Issue 9, 2003, Pages 1347-1354

  Yoshiji, H ^a   Kuriyama, S ^b   Yoshii, J ^a   Ikenaka, Y ^a   Noguchi, R ^a   Hicklin, D J ^c   Wu, Y ^c   Yanase, K ^a   Namisaki, T ^a   Yamazaki, M ^a   Tsujinoue, H ^a   Imazu, H ^a   Masaki, T ^b   Fukui, H ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; CARBON TETRACHLORIDE; HYDROXYPROLINE; MESSENGER RNA; MONOCLONAL ANTIBODY; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; LIVER FIBROSIS; LIVER SINUSOID; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; STELLATE CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ENDOTHELIAL GROWTH FACTORS; HEPATOCYTES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER CIRRHOSIS; LYMPHOKINES; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS; VON WILLEBRAND FACTOR;

EID: 0042887507     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.9.1347     Document Type: Article

References (58)

1. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999;19:129-40.
2. Park YN, Yang CP, Fernandez GJ, et al. Neoangiogenesis and sinusoidal "capillarization" in dysptastic nodules of the liver. Am J Surg Pathol 1998;22:656-62.
3. Schaffner F, Popper H. Capillarization of hepatic sinusoids in man. Gastroenterology 1963;44:239-42.
4. Tanigawa N, Lu C, Mitsui T, et al. Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 1997;26:1216-23.
5. Wisse E, De Zanger RB, Charels K, et al. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. Hepatology 1985;5:683-92.
6. Kalluri R, Sukhatme VP. Fibrosis and angiogenesis. Curr Opin Nephrol Hypertens 2000;9:413-18.
7. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95.
8. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J 1999;18:3964-72.
9. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
10. Ohmori S, Shiraki K, Sugimoto K, et al. High expression of CD34-positive sinusoidal endothelial cells is a risk factor for hepatocellular carcinoma in patients with HCV-associated chronic liver diseases. Hum Pathol 2001;32:1363-70.
11. Corpechot C, Barbu V, Wendum D, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002;35:1010-21.
12. Rosmorduc O, Wendum D, Corpechot C, et al. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol 1999;155:1065-73.
13. Wang YQ, Ikeda K, Ikebe T, et al. Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP-470 in rats. Hepatology 2000;32:980-9.
14. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
15. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001;26:25-35.
16. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000;19:5598-605.
17. Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development 1999;126:1149-59.
18. Bruns CJ, Liu W, Davis DW, et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000;89:488-99.
19. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-8.
20. Torimura T, Ueno T, Kin M, et al. VEGF participates in neovascularization and sinusoidal capillarization in HCC. Cells Hepatic Sinusoid 1999;7:300-301.
21. Mashiba S, Mochida S, Ishikawa K, et al. Inhibition of hepatic stellate cell contraction during activation in vitro by vascular endothelial growth factor in association with upregulation of FLT tyrosine kinase receptor family, FLT-1. Biochem Biophys Res Commun 1999;258:674-8.
22. Ishikawa K, Mochida S, Mashiba S, et al. Expressions of vascular endothelial growth factor in nonparenchymal as well as parenchymal cells in rat liver after necrosis. Biochem Biophys Res Commun 1999;254:587-93.
23. Ankoma-Sey V, Wang Y, Dai Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 2000;31:141-8.
24. Ankoma-Sey V, Matli M, Chang KB, et al. Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing. Oncogene 1998;17:115-21.
25. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 2001;33:409-20.
26. Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 1997;272:32521-7.
27. Shibuya M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 1995;67:281-316.
28. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-95.
29. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999;237:1-30.
30. Adini A, Kornaga T, Firoozbakht F, et al. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 2002;62:2749-52.
31. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-201.
32. Hiratsuka S, Maru Y, Okada A, et al. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001;61:1207-13.
33. Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002;8:841-9.
34. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-40.
35. Yoshiji H, Kuriyama S, Hicklin DJ, et al. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 1999;30:1179-86.
36. Yoshiji H, Kuriyama S, Hicklin DJ, et al. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 2001;33:841-7.
37. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-18.
38. Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-50.
39. Yoshiji H, Yoshii J, Ikenaka Y, et al. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 2002;37:22-30.
40. Yoshiji H, Kuriyama S, Miyamoto Y, et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000;32:1248-54.
41. Yoshiji H, Kuriyama S, Yoshii J, et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 2002;35:834-42.
42. Rockwell P, Neufeld G, Glassman A, et al. In vitro neutralization of vascular endothelial growth factor activation of flk-1 by a monoclonal antibody. Mol Cell Differ 1995;3:91-109.
43. Friedman SL, Roll FJ, Boyles J, et al. Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix. J Biol Chem 1989;264:10756-62.
44. Seetharam L, Gotoh N, Maru Y, et al. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995;10:135-47.
45. Yamane A, Seetharam L, Yamaguchi S, et al. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene 1994;9:2683-90.
46. Yoshiji H, Harris SR, Raso E, et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 1998;75:81-7.
47. Nakatsukasa H, Evarts RP, Hsia CC, et al. Transforming growth factor-beta 1 and type I procollagen transcripts during regeneration and early fibrosis of rat liver. Lab Invest 1990;63:171-80.
48. Lindsay CK, Sinha CC, Thorgeirsson UP. Morphological study of vascular dissemination in a metastatic hepatocellular carcinoma model in the monkey. Hepatology 1997;26:1209-15.
49. Hellwig SM, Damen CA, van Adrichem NP, et al. Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors. Cancer Lett 1997;120:203-11.
50. Friedman SL, Arthur MJ. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest 1989;84:1780-5.
51. Tada H, Shiho O, Kuroshima K, et al. An improved colorimetric assay for interleukin 2. J Immunol Methods 1986;93:157-65.
52. Cui S, Hano H, Sakata A, et al. Enhanced CD34 expression of sinusoid-like vascular endothelial cells in hepatocellular carcinoma. Pathol Int 1996;46:751-6.
53. El-Assal ON, Yamanoi A, Soda Y, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998;27:1554-62.
54. Arthur MJ, Mann DA, Iredale JP. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol 1998;13(suppl):S33-8.
55. Suzuma K, Naruse K, Suzuma I, et al. Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3- kinase-akt-dependent pathways in retinal vascular cells. J Biol Chem 2000;275:40725-31.
56. Jarnagin WR, Rockey DC, Koteliansky VE, et al. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 1994;127(6 Pt 2):2037-48.
57. Maher JJ, McGuire RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest 1990;86:1641-8.
58. Roskams T, Moshage H, De Vos R, et al. Heparan sulfate proteoglycan expression in normal human liver. Hepatology 1995;21:950-8.